Brugada syndrome might stay undetected in patients until surviving cardiac arrest. Despite the prominent advances in exploring the disease in the past 2 decades, many questions remain unanswered and the controversies continue. Despite all mutations identified to be associated with the disease, two-thirds of cases have a negative genetic test. Future studies should be more directed on modulating factors and their impact on patients' risk for sudden death to help physicians in risk stratifying their patients and optimally implementing an implantable cardioverter defibrillator to prevent sudden cardiac death.